Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JOKER: Autologous c-kit-positive CSCs in Ischemic Cardiomyopathy
NCT03351400Phase 1Unknown
- Sponsor
- Sakakibara Heart Institute
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous c-kit-positive cardiac stem cells in ischemic cardiomyopathy (ICM), sponsored by Sakakibara Heart Institute. Primary endpoint: Monitoring adverse events at 2 years. Status: unknown.
02
Drugs
autologous c-kit-positive cardiac stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT03351400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351400.